Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
ViroChem Pharma
Montreal, Quebec, Canadavirochempharma.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
ViroChem Pharma was a Montreal-based biotech company specializing in the discovery and development of antiviral therapeutics. At the time of its acquisition by Vertex Pharmaceuticals for approximately $375 million in March 2009, it had two promising hepatitis C virus polymerase inhibitors—VCH‑222 and VCH‑759—in early-stage clinical development. Both compounds demonstrated significant reductions in plasma HCV RNA as single agents and were well tolerated. The acquisition aimed to complement Vertex's existing HCV protease inhibitor telaprevir pipeline.
- Therapeutic areas
- Infectious Diseases
- Modalities
- small molecules
- Industry
- Biotech
Beyond the preview
Go deeper on ViroChem Pharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ViroChem Pharma.